Loading clinical trials...

COMPLETEDPHASE4

Medicine-induced Cardiac Hemodialysis on COVID-19

Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks

NCT05711810•Yang I. Pachankis

View on ClinicalTrials.gov

Summary

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.

Exclusion Criteria

•healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series
•persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)

Locations (1)

Residential Address

Chongqing, Chongqing Municipality, China

Key Dates

Start Date

January 2, 2023

Primary Completion Date

January 10, 2023

Completion Date

January 12, 2023

Last Updated

February 3, 2023

Enrollment

ACTUAL participants

Conditions

Severe Acute Respiratory Syndrome-related CoronavirusRenal DialysisVaccinesMyocarditis AllergicInfection Viral

Interventions

Nifedipine 30 MG

DRUG

Kangzhu BPCB0A-3A

DIAGNOSTIC_TEST

Low Mobility

BEHAVIORAL

Enalapril Maleate 10Mg Tab

DRUG

Lansoprazole 30Mg Ec Cap

DRUG

Metoprolol Succinate

DRUG

Coenzyme Q10

DIETARY_SUPPLEMENT

d-alpha tocopherol acetate

DIETARY_SUPPLEMENT

Omega-3

DIETARY_SUPPLEMENT

Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release

DRUG

Superoxide Dismutase

DRUG

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898

Papillomavirus VaccinesHuman Immunodeficiency Virus+5 more

View study

RECRUITING

Toxicokinetics of Protein-bound Uremic Toxins in ESRD Patients

NCT05755503

Uremic; ToxemiaPharmacokinetics+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Medicine-induced Cardiac Hemodialysis on COVID-19

Inclusion Criteria

Exclusion Criteria

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

Toxicokinetics of Protein-bound Uremic Toxins in ESRD Patients

Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

Improving Continuous Renal Replacement Therapy Outcomes in Neonates and Infants Through Interdisciplinary Collaboration

Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination

Korea Comirnaty Post-marketing Surveillance